Healthcare
MHRA expands sandbox testing for adaptive medical AI
The UK’s MHRA opened applications for AI Airlock Phase 3, a sandbox focused on post-market surveillance of adaptive medical AI.
The UK’s MHRA opened applications for the third phase of its AI Airlock regulatory sandbox, according to the European health-technology roundup. The sandbox is intended to test live post-market surveillance for adaptive medical AI. The report says draft guidance on managing continuously learning models is scheduled for December 2026. Adaptive systems can change after deployment, making ongoing monitoring important for safety and regulatory oversight. The initiative therefore addresses the full lifecycle of AI-enabled medical technology rather than only pre-market approval. The source does not name participating companies or provide results from earlier phases. Its importance lies in creating a controlled environment for regulators and developers to examine how post-market monitoring could work for AI systems that evolve over time.
Original source: Healthcare.digital